Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SARS-CoV-2 Acute Respiratory Disease Clear all
Completed Phase 2 Interventional

Amantadine Therapy for Cognitive Impairment in Long COVID

NCT06055244
View directory record Official record
Conditions
Long COVID, Post-COVID19 Condition, Post-Acute COVID19 Syndrome
Interventions
Amantadine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 24, 2026, 4:23 AM EDT
Completed No phase listed Observational

Stellate Ganglion Block to Treat Long COVID 19 Case Series

NCT05812209
View directory record Official record
Conditions
Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome, Dysautonomia, Anosmia, Dysgeusia, Brain Fog, Muscle Pain, Shortness of Breath, Dizziness, Fatigue Post Viral, Cough, Menstrual Cycle Abnormal, Pain
Interventions
Stellate Ganglion Block
Procedure
Lead sponsor
Metamorphosis LTD
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cañon City, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Jul 24, 2026, 4:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

NCT05042193
View directory record Official record
Conditions
SARS-CoV-2 Acute Respiratory Disease
Interventions
SARS-CoV-2
Other
Lead sponsor
Everly Health
Industry
Eligibility
18 Years and older
Enrollment
1,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jul 24, 2026, 4:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Virtual Study of Patient Reported Behaviors and Health Outcomes in Individuals With COVID-19

NCT05042232
View directory record Official record
Conditions
SARS-CoV-2 Acute Respiratory Disease
Interventions
SARS-CoV-2 Positive, SARS-CoV-2 Negative
Other
Lead sponsor
Everly Health
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jul 24, 2026, 4:23 AM EDT
Completed No phase listed Observational

Blood Volume Assessment in COVID-19 and Bacterial Sepsis

NCT04517695
View directory record Official record
Conditions
Covid19, Acute Respiratory Distress Syndrome, Bacterial Sepsis, Bacterial Infections
Interventions
BVA-100, Transpulmonary Thermodilution (TPTD), Sublingual Microcirculation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Bethesda, Maryland • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients

NCT04954157
View directory record Official record
Conditions
Hypoxia, SARS-CoV-2 Acute Respiratory Disease, Carotid Bodies
Interventions
Phase-1: Breath Holding Test, Phase 2: 6-Minute Walk Test (6MWT)
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782
View directory record Official record
Conditions
COVID-19, Hypoxia
Interventions
L-ascorbic acid
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT04510194
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Metformin, Placebo, Fluvoxamine, Ivermectin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 85 Years
Enrollment
1,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

NCT04448756
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
M5049, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Jul 24, 2026, 4:23 AM EDT
Withdrawn Phase 1 Interventional

Intermediate IND Severe Illness COVID-19 CP

NCT04411602
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, COVID
Interventions
SARS-CoV-2 plasma
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Novi, Michigan • Southfield, Michigan • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Paxlovid for Treatment of Long Covid

NCT05576662
View directory record Official record
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Interventions
Nirmatrelvir, Placebo, Ritonavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 24, 2026, 4:23 AM EDT
No Longer Available No phase listed Expanded access

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, SARS-CoV Infection
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

NCT04756141
View directory record Official record
Conditions
Diabetes Mellitus, Covid19
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Jul 24, 2026, 4:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir, PF-07321332
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jul 24, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

NCT06161688
View directory record Official record
Conditions
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
Interventions
Ensitrelvir, Placebo
Drug · Other
Lead sponsor
Timothy Henrich
Other
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 24, 2026, 4:23 AM EDT
Not yet recruiting Not applicable Interventional

Personalized Ventilator Settings for Patients on ECMO

NCT07673250
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation, Respiratory Failure Patients Treated With ECMO, Respiratory Failure, ICU, Ventilator Induced Lung Injury
Interventions
Personalized Positive End-Expiratory Pressure (PEEP)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 4:23 AM EDT
Active, not recruiting Phase 2 Interventional

NE3107 in Adults With Neurological Symptoms of Long COVID

NCT06847191
View directory record Official record
Conditions
Long COVID
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 4:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness

NCT05175690
View directory record Official record
Conditions
COVID19
Interventions
Diagnostic Software as Medical Device
Diagnostic Test
Lead sponsor
AudibleHealth AI, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 24, 2026, 4:23 AM EDT
Recruiting Not applicable Interventional

Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome

NCT05977179
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, Fatigue
Interventions
Dietary intervention to mitigate Post-Acute COVID-19 Syndrome, Attention Control
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
50 Years to 94 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 24, 2026, 4:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

TaiChi-DTx for Treating Long Covid Symptoms

NCT05419219
View directory record Official record
Conditions
Fatigue, Dyspnea, Cognitive Impairment, Muscle Pain
Interventions
the multi-domain Tai Chi Digital therapy Software Application
Device
Lead sponsor
Tim Shi
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ellicott City, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jul 24, 2026, 4:23 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

NCT04992273
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 24, 2026, 4:23 AM EDT